Lewes, DE -- (SBWIRE) -- 08/08/2018 -- Short Bowel Syndrome (SBS) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Short Bowel Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Short Bowel Syndrome from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027

Short Bowel Syndrome - Disease Understanding and Treatment Algorithm
Short Bowel Syndrome is the malabsorptive condition which occurs due to the massive resection of the small intestine. It also occurs due to the surgical resection of the small intestine for Crohn disease, trauma, malignancy, radiation, or mesenteric ischemia. It is the most common cause of intestinal failure in children. Short bowel syndrome is characterized by signs and symptoms such as cramping, fatigue, weakness, weight loss and malnutrition and Heartburn.

The Publisher Short Bowel Syndrome market report gives the thorough understanding of the Short Bowel Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Short Bowel Syndrome in the US, Europe, and Japan.

Short Bowel Syndrome Epidemiology
The Short Bowel Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Publisher report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Short Bowel Syndrome in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

As per Crohn's & Colitis Foundation of America, approximately 10,000–20,000 people are suffering from Short Bowel Syndrome in the United States. As per National Organization of Rare Disease, Short Bowel Syndrome affects males and females in equal numbers.
Short Bowel Syndrome Drug Chapters
This segment of the Short Bowel Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Treatment of Short Bowel Syndrome depends on the specific symptoms observed among the patients. Therapeutic market is driven by the use of proton pump inhibitors, choleretic agents, anti-secretin agents and teduglutide for the treatment of Short Bowel Syndrome. Proton pump inhibitors are recommended for treating too much gastric acid secretion among the patients with Short Bowel Syndrome. Choleretic agents are effective in preventing liver disease and improving bile flow. Anti-secretin agents are used for reducing the gastric acid in the intestine. Physicians recommend growth hormones for improving the intestinal absorption among the patients.

Short Bowel Syndrome Market Outlook
The Short Bowel Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Major players such as Zealand Pharma and many others are involved in developing therapies for Short Bowel Syndrome. Launch of emerging therapies such as Glepaglutide (Zealand Pharma A/S.), and SHP633 (Shire Plc.) are expected to change the treatment landscape in upcoming years.

Short Bowel Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
?
Short Bowel Syndrome Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies

Short Bowel Syndrome Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake

Short Bowel Syndrome Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits
- This Publisher report will help to develop Business Strategies by understanding the trends shaping and driving Short Bowel Syndrome market
- Organize sales and marketing efforts by identifying the best opportunities for Short Bowel Syndrome market
- To understand the future market competition in the Short Bowel Syndrome market.

Spanning over 120 pages "Short Bowel Syndrome (SBS) - Market Insights, Epidemiology and Market Forecast-2027" report covers Report Introduction, Short Bowel Syndrome Market Overview at a Glance, Disease Background and Overview: Short Bowel Syndrome, Epidemiology and Patient Population, Treatment Practices, Marketed Products, Key Emerging Therapies, Short Bowel Syndrome Market Size, Report Methodology.

Please visit this link for more details: https://www.marketresearchreports.com/delveinsight/short-bowel-syndrome-sbs-market-insights-epidemiology-and-market-forecast-2027

Find all Drug Pipeline Reports at: https://www.marketresearchreports.com/drug-pipeline

For related reports please visit: https://www.marketresearchreports.com/search/site/Short%2520Bowel%2520Syndrome

Read our Interactive Market Research Blog

About MarketResearchReprots.com
MarketResearchReprots.com is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: https://www.marketresearchreports.com/contact